Symbols / INDP
INDP Chart
About
Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 4.42M |
| Enterprise Value | -2.30M | Income | -16.87M | Sales | — |
| Book/sh | 2.81 | Cash/sh | 3.33 | Dividend Yield | — |
| Payout | 0.00% | Employees | 7 | IPO | — |
| P/E | — | Forward P/E | -1.42 | PEG | — |
| P/S | — | P/B | 0.70 | P/C | — |
| EV/EBITDA | 0.14 | EV/Sales | — | Quick Ratio | 2.61 |
| Current Ratio | 2.88 | Debt/Eq | 0.19 | LT Debt/Eq | — |
| EPS (ttm) | -29.03 | EPS next Y | -1.39 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-12 08:00 | ROA | -131.38% |
| ROE | -3.18% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 2.24M |
| Shs Float | 940.38K | Short Float | 1.64% | Short Ratio | 0.15 |
| Short Interest | — | 52W High | 47.60 | 52W Low | 1.52 |
| Beta | 1.00 | Avg Volume | 716.30K | Volume | 14.31K |
| Target Price | $10.00 | Recom | None | Prev Close | $2.02 |
| Price | $1.97 | Change | -2.48% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$10.00
Mean price target
2. Current target
$1.97
Latest analyst target
3. DCF / Fair value
$-74.63
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.97
Low
$10.00
High
$10.00
Mean
$10.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2024-11-13 | main | Maxim Group | Buy → Buy | $5 |
| 2024-10-16 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-06-17 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-04-15 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2023-09-20 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2023-08-15 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2023-08-11 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2023-08-08 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2023-05-04 | reit | HC Wainwright & Co. | — → Buy | $12 |
| 2023-03-20 | main | HC Wainwright & Co. | — → Buy | $12 |
| 2023-03-08 | reit | HC Wainwright & Co. | — → Overweight | $15 |
| 2023-02-08 | reit | HC Wainwright & Co. | — → Buy | $15 |
| 2021-10-19 | up | Maxim Group | Hold → Buy | $16 |
- Indaptus Therapeutics (INDP) Stock in Focus on Dec. 24, 2025: $6M Financing, Leadership Reset, and the Dilution Question - TechStock² Wed, 24 Dec 2025 08
- Why Did INDP Stock Gain 12% Today? - Stocktwits Mon, 29 Dec 2025 08
- Indaptus Therapeutics Reprices Warrants to Bolster Shareholder Support - TipRanks hu, 12 Feb 2026 08
- Why Did Indaptus Therapeutics Surge 64% In After-Hours Trading? - Benzinga ue, 23 Dec 2025 08
- Indaptus Therapeutics Signs Securities Purchase Agreement With David Lazar - TradingView ue, 23 Dec 2025 08
- Indaptus Therapeutics stock falls after $6 million securities deal - Investing.com Mon, 29 Dec 2025 08
- Is It Too Late to Buy INDP Stock? - timothysykes.com Wed, 24 Dec 2025 08
- Behavioral Patterns of INDP and Institutional Flows - Stock Traders Daily Fri, 30 Jan 2026 00
- Indaptus Therapeutics, Inc. Announces One-for-Twenty-Eight Reverse Stock Split to Enhance Nasdaq Compliance and Attract Investors - Nasdaq Wed, 25 Jun 2025 07
- Indaptus Therapeutics Reports Q3 2025 Financial Results and Corporate Update - Quiver Quantitative Wed, 12 Nov 2025 08
- Indaptus Therapeutics Inc.: Are They Ready for Takeoff? - StocksToTrade Wed, 24 Dec 2025 08
- Indaptus Therapeutics Announces Reverse Stock Split - citybiz Wed, 25 Jun 2025 07
- EXCLUSIVE: Indaptus Therapeutics Starts Phase 1 Combination Study of Decoy20 With BeiGene's Cancer Drug For Advanced Solid Tumors - Yahoo Finance ue, 18 Mar 2025 07
- Indaptus Therapeutics, Uipath, Trinity Biotech, Sable Offshore And McDonald's: Why These 5 Stocks Are On Investors' Radars Today - Benzinga ue, 23 Dec 2025 08
- U.S. Stock Market Preview | Initial jobless claims data came in below expectations, with the three major index futures remaining stable; Biotech stocks led gains in pre-market trading, with INDP surging over 58%; U.S. stocks will close early on Christmas - 富途牛牛 Wed, 24 Dec 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 25000 | — | — | Stock Award(Grant) at price 0.00 per share. | BEN-TZVI AVRAHAM | Director | — | 2026-01-20 00:00:00 | D |
| 1 | 216617 | 439733 | — | Stock Award(Grant) at price 2.03 per share. | MECKLER JEFFREY A | Chief Executive Officer | — | 2025-12-22 00:00:00 | D |
| 2 | 54421 | 110475 | — | Stock Award(Grant) at price 2.03 per share. | LINSCOTT WALT ADDISON ESQ. | Chief Operating Officer | — | 2025-12-22 00:00:00 | D |
| 3 | 26758 | 54319 | — | Stock Award(Grant) at price 2.03 per share. | SASSI NIR | Chief Financial Officer | — | 2025-12-22 00:00:00 | D |
| 4 | 52204 | 105974 | — | Stock Award(Grant) at price 2.03 per share. | NEWMAN MICHAEL JAMES | Officer and Director | — | 2025-12-22 00:00:00 | D |
| 5 | 6068 | 50379 | — | Stock Award(Grant) at price 8.30 per share. | MECKLER JEFFREY A | Chief Executive Officer | — | 2025-07-25 00:00:00 | D |
| 6 | 42553 | 50000 | — | Stock Award(Grant) at price 1.18 per share. | MECKLER JEFFREY A | Chief Executive Officer | — | 2024-11-25 00:00:00 | D |
| 7 | 84932 | 155001 | — | Stock Award(Grant) at price 1.82 per share. | MECKLER JEFFREY A | Chief Executive Officer | — | 2024-08-08 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -15.37M | -16.38M | -14.91M | -7.73M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -15.02M | -15.42M | -14.32M | -7.71M |
| ReconciledDepreciation | 735.00 | 1.28K | 1.78K | 1.40K |
| EBITDA | -15.37M | -16.38M | -14.91M | -7.73M |
| EBIT | -15.37M | -16.38M | -14.91M | -7.73M |
| NetInterestIncome | 588.11K | 17.72K | ||
| InterestIncome | 588.11K | 17.72K | ||
| NormalizedIncome | -15.02M | -15.42M | -14.32M | -7.71M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -15.02M | -15.42M | -14.32M | -7.71M |
| TotalExpenses | 15.37M | 16.38M | 14.91M | 7.73M |
| TotalOperatingIncomeAsReported | -15.37M | -16.38M | -14.91M | -7.73M |
| DilutedAverageShares | 334.13K | 300.04K | 295.07K | 146.09K |
| BasicAverageShares | 334.13K | 300.04K | 295.07K | 146.09K |
| DilutedEPS | -45.08 | -51.24 | -48.44 | -52.92 |
| BasicEPS | -45.08 | -51.24 | -48.44 | -52.92 |
| DilutedNIAvailtoComStockholders | -15.02M | -15.42M | -14.32M | -7.71M |
| NetIncomeCommonStockholders | -15.02M | -15.42M | -14.32M | -7.71M |
| NetIncome | -15.02M | -15.42M | -14.32M | -7.71M |
| NetIncomeIncludingNoncontrollingInterests | -15.02M | -15.42M | -14.32M | -7.71M |
| NetIncomeContinuousOperations | -15.02M | -15.42M | -14.32M | -7.71M |
| PretaxIncome | -15.02M | -15.42M | -14.32M | -7.71M |
| OtherIncomeExpense | 343.72K | 955.00K | 588.11K | |
| OtherNonOperatingIncomeExpenses | 343.72K | 955.00K | 588.11K | |
| NetNonOperatingInterestIncomeExpense | 588.11K | 17.72K | ||
| InterestIncomeNonOperating | 588.11K | 17.72K | ||
| OperatingIncome | -15.37M | -16.38M | -14.91M | -7.73M |
| OperatingExpense | 15.37M | 16.38M | 14.91M | 7.73M |
| ResearchAndDevelopment | 7.25M | 7.62M | 6.32M | 2.52M |
| SellingGeneralAndAdministration | 8.11M | 8.76M | 8.59M | 5.21M |
| GeneralAndAdministrativeExpense | 8.11M | 8.76M | 8.59M | 5.21M |
| OtherGandA | 8.11M | 8.76M | 8.59M | 5.21M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 429.07K | 300.04K | 300.04K | 294.95K |
| ShareIssued | 429.07K | 300.04K | 300.04K | 294.95K |
| TotalDebt | 84.16K | 175.05K | 80.49K | 169.33K |
| TangibleBookValue | 3.94M | 12.08M | 24.63M | 35.90M |
| InvestedCapital | 3.94M | 12.08M | 24.63M | 35.90M |
| WorkingCapital | 3.22M | 11.22M | 23.81M | 35.78M |
| NetTangibleAssets | 3.94M | 12.08M | 24.63M | 35.90M |
| CapitalLeaseObligations | 84.16K | 175.05K | 80.49K | 169.33K |
| CommonStockEquity | 3.94M | 12.08M | 24.63M | 35.90M |
| TotalCapitalization | 3.94M | 12.08M | 24.63M | 35.90M |
| TotalEquityGrossMinorityInterest | 3.94M | 12.08M | 24.63M | 35.90M |
| StockholdersEquity | 3.94M | 12.08M | 24.63M | 35.90M |
| GainsLossesNotAffectingRetainedEarnings | 0.00 | 96.43K | 0.00 | |
| OtherEquityAdjustments | 96.43K | |||
| RetainedEarnings | -60.44M | -45.42M | -29.99M | -15.67M |
| AdditionalPaidInCapital | 64.26M | 57.41M | 54.44M | 51.49M |
| CapitalStock | 120.14K | 84.01K | 84.01K | 82.59K |
| CommonStock | 120.14K | 84.01K | 84.01K | 82.59K |
| PreferredStock | 0.00 | 0.00 | 0.00 | |
| TotalLiabilitiesNetMinorityInterest | 3.39M | 2.85M | 3.43M | 4.68M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 0.00 | 73.35K | 0.00 | 72.86K |
| LongTermDebtAndCapitalLeaseObligation | 0.00 | 73.35K | 0.00 | 72.86K |
| LongTermCapitalLeaseObligation | 0.00 | 73.35K | 0.00 | 72.86K |
| CurrentLiabilities | 3.39M | 2.77M | 3.43M | 4.60M |
| CurrentDebtAndCapitalLeaseObligation | 84.16K | 101.70K | 80.49K | 96.47K |
| CurrentCapitalLeaseObligation | 84.16K | 101.70K | 80.49K | 96.47K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 1.37M | 1.21M | 1.22M | 1.37M |
| PayablesAndAccruedExpenses | 1.94M | 1.46M | 2.14M | 3.14M |
| CurrentAccruedExpenses | 1.07M | 613.27K | 629.36K | 498.73K |
| Payables | 870.23K | 846.00K | 1.51M | 2.64M |
| TotalTaxPayable | 0.00 | 40.00K | 128.93K | 97.72K |
| AccountsPayable | 870.23K | 806.00K | 1.38M | 2.54M |
| TotalAssets | 7.34M | 14.92M | 28.06M | 40.58M |
| TotalNonCurrentAssets | 720.43K | 928.67K | 819.56K | 189.37K |
| OtherNonCurrentAssets | 754.73K | 738.25K | 16.48K | |
| NonCurrentPrepaidAssets | 638.25K | 754.73K | ||
| NetPPE | 82.17K | 173.94K | 81.31K | 172.89K |
| GrossPPE | 82.17K | 173.94K | 81.31K | 172.89K |
| OtherProperties | 82.17K | 173.94K | 81.31K | 172.89K |
| BuildingsAndImprovements | 173.21K | 79.29K | 169.09K | |
| Properties | 0.00 | 0.00 | 0.00 | |
| CurrentAssets | 6.62M | 14.00M | 27.24M | 40.39M |
| AssetsHeldForSaleCurrent | 0.00 | 148.40K | ||
| PrepaidAssets | 831.58K | 633.16K | 811.43K | 1.09M |
| Receivables | 0.00 | 21.06K | ||
| OtherReceivables | 21.06K | |||
| CashCashEquivalentsAndShortTermInvestments | 5.79M | 13.36M | 26.43M | 39.13M |
| OtherShortTermInvestments | 0.00 | 16.81M | 0.00 | |
| CashAndCashEquivalents | 5.79M | 13.36M | 9.63M | 39.13M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -12.32M | -13.41M | -13.08M | -11.29M |
| IssuanceOfCapitalStock | 5.51M | 0.00 | 0.00 | 5.00M |
| CapitalExpenditure | -3.85K | |||
| InterestPaidSupplementalData | 5.14K | |||
| IncomeTaxPaidSupplementalData | 1.60K | 1.60K | 2.40K | 800.00 |
| EndCashPosition | 5.79M | 13.36M | 9.63M | 39.13M |
| BeginningCashPosition | 13.36M | 9.63M | 39.13M | 1.64M |
| ChangesInCash | -7.58M | 3.74M | -29.51M | 37.49M |
| FinancingCashFlow | 4.75M | 0.00 | 0.00 | 48.34M |
| CashFlowFromContinuingFinancingActivities | 4.75M | 0.00 | 0.00 | 48.34M |
| NetOtherFinancingCharges | -762.70K | 12.97M | ||
| ProceedsFromStockOptionExercised | 0.00 | 30.36M | ||
| NetCommonStockIssuance | 5.51M | 0.00 | 0.00 | 5.00M |
| CommonStockIssuance | 5.51M | 0.00 | 0.00 | 5.00M |
| InvestingCashFlow | 0.00 | 17.14M | -16.43M | 447.75K |
| CashFlowFromContinuingInvestingActivities | 0.00 | 17.14M | -16.43M | 447.75K |
| NetOtherInvestingChanges | 172.56K | 451.60K | ||
| NetInvestmentPurchaseAndSale | 0.00 | 17.14M | -16.60M | 0.00 |
| SaleOfInvestment | 0.00 | 24.00M | 13.00M | 0.00 |
| PurchaseOfInvestment | 0.00 | -6.86M | -29.60M | 0.00 |
| NetPPEPurchaseAndSale | 0.00 | -3.85K | ||
| PurchaseOfPPE | 0.00 | -3.85K | ||
| OperatingCashFlow | -12.32M | -13.41M | -13.08M | -11.29M |
| CashFlowFromContinuingOperatingActivities | -12.32M | -13.41M | -13.08M | -11.29M |
| ChangeInWorkingCapital | 392.25K | -518.07K | -1.58M | -5.09M |
| ChangeInOtherWorkingCapital | 142.00 | 647.00 | 961.00 | 240.00 |
| ChangeInOtherCurrentAssets | 0.00 | -721.77K | -16.48K | |
| ChangeInPayablesAndAccruedExpense | 474.06K | -680.52K | -1.15M | -4.24M |
| ChangeInPayable | 474.06K | -680.52K | -1.15M | -4.24M |
| ChangeInAccountPayable | 474.06K | -680.52K | -1.15M | -4.24M |
| ChangeInPrepaidAssets | -81.94K | 161.80K | 295.22K | -837.92K |
| OtherNonCashItems | -430.99K | -110.00K | ||
| StockBasedCompensation | 2.31M | 2.97M | 2.96M | 1.51M |
| DepreciationAmortizationDepletion | 735.00 | 1.28K | 1.78K | 1.40K |
| DepreciationAndAmortization | 735.00 | 1.28K | 1.78K | 1.40K |
| Depreciation | 735.00 | 1.28K | 1.78K | 1.40K |
| OperatingGainsLosses | -24.16K | |||
| GainLossOnInvestmentSecurities | -110.00K | |||
| NetIncomeFromContinuingOperations | -15.02M | -15.42M | -14.32M | -7.71M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for INDP
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|